SecBot SecBot
PRESS-RELEASE ·Filed Nov 5, 2026

CRVS

Corvus Pharmaceuticals, Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed11d 10h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

Monitor upcoming data readouts: Angel Pharma cohort 1 topline in March 2027, HS initial data in 1H 2027, and ASH presentation in December 2026 for ALPS data. Cash runway into Q2 2028 reduces near-term financing risk.

DirectionNeutral
Confidencehigh
Horizonmonths

soquelitinib

● Neutral Named in this press release
Impact
Phase
Phase 3 (registrational for PTCL); Phase 2 (atopic dermatitis, ALPS); Phase 1b (hidradenitis suppurativa)
Time to market
If the Phase 3 PTCL trial succeeds at its interim futility analysis (Q1 2027) and final readout (estimated primary completion November 2027), a potential NDA submission could occur in 2028, with FDA approval possible in 2029 at the earliest. The atopic dermatitis program is earlier-stage (Phase 2 topline in Q3 2027) and would require additional Phase 3 trials before any regulatory submission.
Next catalyst
None dated

What to watchThe next major binary catalyst is the Phase 3 PTCL interim futility analysis expected in Q1 2027 (roughly 2-5 months away). A positive result would validate soquelitinib's novel ITK-inhibitor mechanism in oncology and support continued enrollment toward the primary completion in late 2027. A futility stop would severely damage the thesis. Separately, the SIERRA1 atopic dermatitis Phase 2 topline data in Q3 2027 will test the drug's potential in a large immunology market. The ASH 2026 poster (Dec 14) on ALPS data (n=3) is an early readout with limited stock-moving potential.

Price Chart

Loading chart...

Executive Summary

Corvus Pharmaceuticals reported Q3 2026 net loss of $20.3M ($0.22 per share), wider than the $10.2M loss in Q3 2025, driven by higher R&D costs for soquelitinib trials. Cash runway extends into Q2 2028 with $202.9M at quarter end. Key pipeline milestones include ALPS Phase 2 positive initial data, Angel Pharma cohort 1 enrollment complete with topline data expected March 2027, and Phase 1b HS trial enrolling with initial data in 1H 2027.

Key Financial Metrics

EPS
−$0.22

Key Facts

  • Q3 2026 net loss of $20.3M vs $10.2M in Q3 2025
  • R&D expenses $17.8M, up from $8.5M year-over-year
  • Cash, cash equivalents and marketable securities $202.9M at September 30, 2026
  • Cash runway extends into Q2 2028
  • Phase 3 PTCL and Phase 2 atopic dermatitis trials on track
  • Angel Pharma completes enrollment in cohort 1 of Phase 1b/2 atopic dermatitis trial; topline data March 2027
  • Phase 1b hidradenitis suppurativa trial enrolling; initial data 1H 2027
  • Phase 2 asthma trial to initiate by Q1 2027
  • ALPS Phase 2 initial data positive; poster at ASH December 2026
  • Net loss per share $0.22 (basic and diluted) vs $0.12 in Q3 2025

Financial Impact

Net loss widened by $10.1M to $20.3M; R&D spend increased $9.3M to $17.8M; cash position $202.9M provides runway into Q2 2028

net lossR&D expensescash position

Risk Factors

  • Wider net loss driven by increased R&D spending with no near-term revenue
  • Clinical-stage biotech with no approved products; all pipeline candidates are investigational
  • Reliance on successful clinical trial outcomes for soquelitinib across multiple indications

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
92% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3396993

Track record

15 reports on CRVS

Performance horizon

1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +2.61% at T+1 after the Mar 12, 2026 report. 2 of 3 went positive at some point.

Filters
  1. Nov 13, 20263d ago Insider Buy Neutral 3/10 Entry $11.20 Now $10.60 −5.36% settles Feb 12
  2. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $11.37 Now $10.60 −6.77% settles Feb 8
  3. Nov 5, 202611d ago 8-K Neutral 4/10 Entry $10.54 Now $10.60 +0.57% settles Feb 4
  4. Nov 5, 202611d ago Press Release Neutral 4/10 Viewing No price data
  5. Nov 4, 202612d ago Press Release Neutral 4/10 Entry $10.57 Now $10.60 +0.28% settles Feb 2
  6. Sep 30, 20266w ago Press Release Neutral 3/10 Entry $10.93 Now $10.60 −3.02% settles Dec 28
  7. Aug 21, 202612w ago Institutional Cluster Bullish 6/10 Entry $14.46 to $10.60 Now $10.60 −26.69% ▼ −26.69% −23.33% vs SPY
  8. Jul 22, 202616w ago 8-K Neutral 2/10 Entry $13.68 to $9.85 Now $10.60 −22.51% ▼ −28.00% −32.55% vs SPY
  9. Jun 11, 202622w ago Institutional Cluster Neutral 3/10 Entry $11.60 to $14.39 Now $10.60 −8.62% ▲ +24.05% +19.66% vs SPY
  10. May 14, 202626w ago 8-K Bullish 7/10 Entry $13.66 to $13.74 Now $10.60 −22.37% ▲ +0.62% −2.97% vs SPY
Showing 10 of 15

US Market Status

Market Closed · Opens in 6h 41m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026